1: (ROOT (S (S (NP (NNP Remdesivir)) (VP (VBG Showing) (NP (NN Promise)) (PP (PP (IN In) (NP (NP (NP (DT Some) (CD COVI-19) (NNP PatientsGilead) (POS 's)) (NN drug) (NN candidate)) (NP (NNP Remdesivir)))) (VP (VBZ is) (VP (VBG showing) (NP (NP (DT some) (NNS signs)) (PP (IN of) (NP (NP (JJ positive) (NN proof)) (PP (IN of) (NP (NN concept)))))) (PP (IN in) (NP (JJ hospitalized) (CD COVI-19) (NNS patients)))))))) (: ;) (S (NP (PRP it)) (VP (VBD outperformed) (NP (NN placebo)) (PP (IN by) (NP (CD 31) (NN %))) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN trial)) (VP (VBN sponsored) (PP (IN by) (NP (DT the) (NNP NIH)))))) (PP (VBG according) (PP (IN to) (NP (DT the) (NN agency)))))) (. .)))
2: (ROOT (S (S (NP (NP (NP (NNP NIH) (POS 's)) (NNP National) (NNP Institute)) (PP (IN of) (NP (NP (NNP Allergy)) (CC and) (NP (NNP Infectious) (NNP Disease))))) (VP (VBZ has) (VP (VBN released) (NP (NP (JJ preliminary) (NNS data)) (VP (VBG showing) (NP (NP (DT the) (NN study)) (VP (VBG meeting) (NP (NP (DT the) (JJ primary) (NN outcome)) (PP (IN of) (NP (NP (JJ statistical) (NN improvement)) (PP (IN in) (NP (NP (NN time)) (PP (IN to) (NP (NN recovery))))) (PP (IN by) (NP (NN day) (CD 29))))))))))))) (: ;) (S (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN treated)))))) (VP (VBD showed) (NP (NP (DT a) (JJ median) (NN time)) (PP (IN to) (NP (NN recovery))) (PP (IN of) (NP (CD 22) (NNS days))) (PP (VBN compared) (PP (IN to) (NP (NP (CD 15) (NNS days)) (PP (IN for) (NP (NP (DT those)) (VP (VBG receiving) (NP (NN placebo))))))))))) (. .)))
3: (ROOT (S (NP (JJ Additional) (NNS data)) (VP (MD will) (VP (VB be) (VP (VBN released) (SBAR (IN while) (S (NP (NP (DT the) (NN study)) (PP (IN with) (NP (NNS results)))) (VP (VBZ is) (VP (VBG being) (VP (VBN submitted) (PP (IN for) (NP (NN publication))) (PP (IN in) (NP (DT a) (ADJP (NN peer) (VBN reviewed)) (NN journal))))))))))) (. .)))
4: (ROOT (S ('' `) (SBAR (IN Although) (S (NP (DT a) (NML (CD 31) (NN %)) (NN improvement)) (VP (VBZ does) (`` ') (RB t) (VP (VB seem) (PP (IN like) (NP (DT a) (NN knockout) (CD 100) (NN %))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB very) (JJ important)) (NN proof)) (PP (IN of) (NP (NN concept))))) (. .)))
5: (ROOT (S (S (SBAR (WHNP (WP What)) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN proven))))) (VP (VBZ is) (SBAR (IN that) (S (NP (DT a) (NN drug)) (VP (MD can) (VP (VB block) (NP (DT this) (NN virus)))))))) (, ,) ('' ') (NP (NML (NNP NIAID) (NNP Director)) (NNP Anthony)) (. .)))
6: (ROOT (S (NP (DT This)) (VP (MD will) (VP (VB be) (NP (NP (DT the) (NN standard)) (PP (IN of) (NP (NN care)))))) (. .) ('' ')))
7: (ROOT (S (SBAR (WHPP (IN To) (WHNP (WDT which))) (S (NP (DT the) (NN president)) (VP (VBD added)))) (, ,) (`` `) (NP (PRP It)) (VP (VBZ 's) (NP (DT a) (NN beginning))) (. .)))
8: (ROOT (S (NP (DT That)) (VP (VBZ means) (SBAR (S (NP (PRP you)) (VP (VBP build) (PP (IN on) (NP (PRP it))))))) (. .)))
9: (ROOT (S (CC But) (NP (PRP it)) (VP (VBZ 's) (NP (DT a) (ADJP (RB very) (JJ positive)) (NN event))) (. .) ('' ')))
10: (ROOT (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (JJ clinical) (NN study)) (VP (VBN launched) (PP (IN in) (NP (NNP America)))) (PP (IN of) (NP (NP (DT a) (JJ possible) (JJ therapeutic)) (PP (IN for) (NP (DT the) (HYPH COVI-19) (NN virus))))))) (. .)))
11: (ROOT (S (NP (NNP Remdesivir)) (VP (VBZ is) (PP (IN among) (NP (NP (CD 18) (JJ other) (NNS candidates)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN designated) (IN as) (S (VP (VBG being) (NP (DT the) (JJ front) (NNS runners)) (PP (IN among) (NP (NP (NP (QP (RB over) (CD 160)) (JJ other) (JJ possible) (NNS therapeutics)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (PP (IN under) (NP (NN study))))))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB be) (VP (VBN viewed) (PP (IN in) (NP (NNP GEN) (VBN updated) (NNP -List))) (PP (IN by) (S (VP (VBG clicking) (ADVP (RB here))))))))))))))))))))) (. .)))
12: (ROOT (S (S (NP (NNP Remdesivir)) (VP (VBD had) (NP (NP (DT a) (NN mortality) (NN rate)) (PP (IN of) (NP (CD 8) (NN %)))) (PP (VBN compared) (PP (IN to) (NP (NP (CD 11) (NN %)) (PP (IN of) (NP (NP (DT those)) (VP (VBG receiving) (NP (NN placebo)))))))))) (, ,) (NP (DT the) (NN agency)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT this)) (VP (VBZ is) (NP (NP (DT a) (NN survival) (NN benefit)) (PP (IN to) (NP (DT the) (NN nucleotide) (NN prodrug)))))))) (. .)))
13: (ROOT (S (NP (DT This) (NN trial)) (VP (VP (VBZ is) (NP (NP (DT an) (ADJP (JJ adaptive)) (, ,) (JJ randomized) (, ,) (NML (JJ double) (JJ blind)) (, ,) (ADJP (NN placebo) (VBN controlled)) (NN trial)) (VP (VBG evaluating) (NP (NP (QP (CD ,) (CD 063)) (JJ hospitalized) (CD COVI-19) (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ broad) (NN range)) (PP (IN of) (NP (NNS symptoms))))))))) (: ;) (CC and) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (NP (CD three) (JJ randomized) (JJ blinded) (NML (NNP Phase) (NNP III)) (NNS studies)) (VP (VBG assessing) (NP (DT the) (NN drug) (NN candidate)))) (VP (VBG involving) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 68) (NNS sites)))))))))) (. .)))
14: (ROOT (S (`` `) (S (PP (VBN Based) (PP (IN upon) (NP (NP (PRP$ their) (NN review)) (PP (IN of) (NP (DT the) (NNS data)))))) (, ,) (NP (PRP they)) (VP (VBD noted) (SBAR (IN that) (S (NP (NN remdesivir)) (VP (VBD was) (ADJP (ADJP (JJR better)) (PP (IN than) (NP (NN placebo)))) (PP (IN from) (NP (NP (DT the) (NN perspective)) (PP (IN of) (NP (NP (DT the) (JJ primary) (NN endpoint)) (, ,) (NP (NP (NN time)) (PP (IN to) (NP (NN recovery))))))))))))) (, ,) ('' ') (NP (NNP NIAID)) (VP (VBD stated)) (. .)))
15: (ROOT (S (NP (NP (NN Recovery)) (PP (IN in) (NP (DT this) (NN study)))) (VP (VBD was) (VP (VBN defined) (PP (IN as) (S (VP (VBG being) (ADJP (ADJP (RB well) (JJ enough) (PP (IN for) (NP (NN hospital) (NN discharge)))) (CC or) (VP (VBG returning) (PP (IN to) (NP (JJ normal) (NN activity) (NN level)))))))))) (. .) ('' ')))
16: (ROOT (S ('' `) (S (VP (VBG Accumulating) (NP (NP (NNS data)) (PP (IN on) (NP (NNP Remdesivir)))))) (VP (VBZ suggests) (SBAR (S (S (NP (PRP it)) (VP (VBZ 's) (ADJP (JJ active) (PP (IN against) (NP (NNP COVID)))))) (CC and) (S (NP (EX there)) (VP (VBZ 's) (ADVP (RB now)) (NP (JJ enough) (NNS data) (S (VP (TO to) (VP (VB support) (NP (NP (NN consideration)) (PP (IN of) (NP (NN access))) (PP (IN under) (NP (NP (DT an) (NN emergency) (NN use) (NN authorization)) (PP (IN by) (NP (NNP FDA))))))))))))))) (. .)))
17: (ROOT (SINV (S (NP (NP (DT The) (NNS data)) (PP (IN from) (NP (NNP NIAID) (NN study)))) (VP (MD should) (VP (VB push) (NP (DT this)) (ADVP (RB firmly)) (PP (IN over) (NP (DT the) (NN line)))))) (, ,) ('' ') (VP (VBZ writes)) (NP (NP (NNP Scott) (NNP Gottlieb)) (, ,) (NP (NNP MD)) (, ,) (NP (JJ former) (NNP FDA) (NNP Commissioner))) (. .)))
18: (ROOT (S (ADVP (RB However)) (, ,) (NP (RB not) (NN everyone)) (VP (VBZ is) (ADJP (RB as) (JJ excited)) (PP (VBG including) (NP (NP (NP (NNP Eric) (NNP Topol)) (, ,) (NP (NNP MD))) (, ,) (SBAR (WHNP (WHNP (WP who)) (S (VP (VBZ is) (NP (NP (DT the) (NN director)) (PP (IN of) (NP (DT the) (NNP Scripps) (NNP Research) (NNP Translational) (NNP Institute)))))) (WHNP (WP who))) (S (VP (VBZ cautions) (`` `) (S (NP (NP (DT The) (JJ new) (NN remdesivir) (NNS data)) (PP (IN from) (NP (NNP Tony) (NNP Fauci))) (PP (IN from) (NP (NML (NNP N) (IN >) (, ,) (CD 000)) (ADJP (NN placeb) (HYPH -) (VBN controlled)) (NN trial)))) (VP (VBZ does) (RB not) (VP (VB show) (NP (NP (NP (ADJP (RB statistically) (JJ significant)) (NN reduction)) (PP (IN in) (NP (NN mortality)))) (CC but) (NP (NP (DT a) (ADJP (NN clea) (HYPH -) (VBN cut)) (NN benefit)) (PP (IN in) (NP (NN time))) (PP (IN to) (NP (NP (NP (NN recovery)) (NP (NP (CD 11)) (IN vs) (NP (CD 15) (NNS days)))) (, ,) (NP (NN P) (. <) (CD .001))))))))))))))) (. .) ('' ')))
19: (ROOT (S (S (NP (DT This)) (VP (VBD was) (NP (NP (NP (QP (RB just) (CD one))) (PP (IN of) (NP (NP (DT the) (CD two) (NN remdesivir) (NNS studies)) (SBAR (WHNP (WDT that)) (S (NP (NNS data)) (VP (VBD was) (VP (VBN released) (PP (IN for))))))))) (, ,) (SBAR (IN as) (S (NP (DT the) (NNP Lancet)) (VP (VBD published) (NP (NP (NNS results)) (VP (VBG showing) (SBAR (IN that) (S (NP (DT the) (NN drug) (NN candidate)) (VP (VBD failed) (S (VP (TO to) (VP (VB show) (NP (NP (JJ clinical) (NNS improvements)) (PP (IN in) (NP (ADJP (RB severely) (VBN infected)) (NNS patients)))) (PP (IN in) (NP (DT a) (JJ Chinese) (NML (NNP Phase) (CD III)) (NN trial))))))))))))))))) (: ;) (S (NP (DT this) (NN trial)) (VP (VBD was) (NP (NP (DT a) (VBN randomised) (, ,) (ADJP (JJ double) (JJ blinded)) (, ,) (ADJP (NN placebo) (VBN controlled)) (JJ multicenter) (NN trial)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN remdesivir)) (VP (VBD failed) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (NN virus))) (PP (IN in) (NP (NP (DT the) (NN bloodstream)) (PP (IN of) (NP (NP (CD 158) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (DT the) (NN candidate))) (PP (IN in) (NP (DT the) (CD 237) (NN patient) (NN trial))))))))))))))))))))) (. .)))
20: (ROOT (S (S (NP (NP (JJ Primary) (NN endpoint)) (PP (IN in) (NP (DT this) (NN trial)))) (VP (VBD was) (NP (NP (NN time)) (PP (IN to) (NP (JJ clinical) (NN improvement)))) (PP (IN up) (PP (IN to) (NP (NN day) (CD 28)))))) (, ,) (NP (NP (DT the) (JJ average) (NN time)) (PP (IN to) (NP (JJ clinical) (NN improvement)))) (VP (VBD was) (NP (NP (NP (CD 21) (NNS days)) (PP (IN for) (NP (NP (DT those)) (VP (VBN treated))))) (CC and) (NP (NP (CD 23)) (PP (IN for) (NP (NP (DT those)) (VP (VBG receiving) (NP (NN placebo)))))))) (. .)))
21: (ROOT (S (PP (NP (CD 28) (NNS days)) (IN after) (NP (NN treatment))) (NP (NP (CD 1.9) (NN %)) (PP (IN of) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN remdesivir) (NN cohort)))))) (VP (VBD died) (PP (VBN compared) (PP (IN to) (NP (NP (CD 1.8) (NN %)) (PP (IN of) (NP (DT the) (NN placebo) (NN group))))))) (. .)))
22: (ROOT (S (PP (IN Of) (NP (DT the) (JJ secondary) (NNS outcomes))) (NP (NP (CD 1.3) (NN %)) (PP (IN in) (NP (DT the) (NN treatment) (NN group)))) (VP (VP (VBD died) (PP (IN within) (NP (NP (CD 10) (NNS days)) (PP (IN of) (NP (NN illness) (NN onset))))) (VBN compared) (PP (IN to) (NP (NP (CD 1.9) (NN %)) (PP (PP (IN of) (NP (NP (DT the) (NN placebo) (CD group.1.6) (NN %)) (PP (IN of) (NP (DT the) (NN treatment) (NN group))))) (VP (VBD were) (VP (VBN taken) (PP (IN off) (PP (IN of) (NP (DT the) (NN drug) (NN candidate)))) (PP (IN due) (IN to) (NP (NP (NN side) (NNS effects)) (PP (VBN compared) (PP (IN to) (NP (NP (CD .1) (NN %)) (PP (IN of) (NP (DT the) (NN placebo) (NN group)))))))))))))) (: ;) (S (NP (JJ adverse) (NNS effects)) (VP (VBD were) (VP (VBN reported) (PP (IN from) (NP (NP (NP (CD 6.8) (NN %)) (PP (IN of) (NP (DT the) (NN remdesivir) (NN group)))) (PP (VBN compared) (PP (IN to) (NP (NP (CD 6.1) (NN %)) (PP (IN of) (NP (DT the) (NN placebo) (NN group)))))))))))) (. .)))
23: (ROOT (S (NP (NP (NP (NP (NNP University)) (PP (IN of) (NP (NNP Chicago)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NN treatment) (NNS sites)) (VP (NNS cautions)))))))) (, ,)) (`` `) (S (VP (VBG Drawing) (NP (DT any) (NNS conclusions)) (PP (IN at) (NP (DT this) (NN point)))))) (VP (VBZ is) (ADJP (ADJP (JJ premature)) (CC and) (ADJP (RB scientifically) (JJ unsound)))) (. .) ('' ')))
